medigraphic.com
Instituto Nacional de Salud Pública

2023, Number 3

<< Back Next >>

salud publica mex 2023; 65 (3)

Disparities on prostate cancer survival in Mexico: a retrospective cohort study

Torres-Sánchez L, Hernández-Pérez JG, Escamilla-Nuñez C, Rodríguez-Covarrubias F, Manzanilla-García H, Mohar A, Morales-Carmona E, Espin-Arellano LI, Hernández-Ávila JE, Lajous M

Language: English
References: 34
Page: 236-244
PDF size: 538.85 Kb.


ABSTRACT

Objective. To estimate prostate cancer (PC) survival in Mexico and explore survival disparities according to the marginalization level of residence place. Materials and methods. A nationwide administrative claims database (4 110 men) whose PC treatment was financed by Seguro Popular between 2012-2016, was cross-linked to the National Mortality Registry up to December 2019. Patients were classified according to their oncological risk at diagnosis and the marginalization level of the residence municipality. Cox proportional hazards regression was used to estimate multivariable survival functions. Results. Five-years PC survival (69%; 95%CI: 68,71%) ranged from 72% to 54% at very low and very high marginalization, respectively (p for trend‹0.001). The lowest PC survival was observed in men with high-risk PC (47%; 95%CI: 33,66%) residents in very high marginalization municipalities. Conclusions. Overall, PC survival was lower than that reported in other Latin American countries. The distribution of oncologic risk and survival differences across marginalization levels suggests limited early detection and cancer health disparities.


REFERENCES

  1. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racialand ethnic disparities in cancer survival: the contribution of tumor,sociodemographic, institutional, and neighborhood characteristics. J ClinOncol. 2018;36(1):25-33. https://doi.org/10.1200/JCO.2017.74.2049

  2. Coughlin SS. A review of social determinants of prostate cancer risk,stage, and survival. Prostate Int. 2020;8(2):49-54. https://doi.org/10.1016/j.prnil.2019.08.001

  3. Lazar M, Davenport L. Barriers to health care access for low incomefamilies: a review of literature. J Community Health Nurs. 2018:35(1);28-37. https://doi.org/10.1080/07370016.2018.1404832

  4. King-Okoye M, Arber A, Faithfull S. Beliefs that contribute to delaysin diagnosis of prostate cancer among Afro-Caribbean men in Trinidadand Tobago. Psychooncology. 2019;28(6):1321-7. https://doi.org/10.1002/pon.5085

  5. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. GlobalCancer Observatory: Cancer Today. Lyon: International Agency forResearch on Cancer, 2021 [cited June 15, 2021]. Available from: https://gco.iarc.fr/today

  6. Vázquez-Salas RA, Torres-Sánchez L, López-Carrillo L, Romero-MartínezM, Manzanilla-García HA, Cruz-Ortíz CH, et al. History of gonorrhea andprostate cancer in a population-based case-control study in Mexico. CancerEpidemiol. 2016;40:95-101. https://doi.org/10.1016/j.canep.2015.12.001

  7. Torres-Sánchez LE, Espinoza-Giacinto R, Rojas-Martínez R, Escamilla-Nuñez C, Vázquez-Salas RA, Campuzano JC, et al. Prostate cancermortality according to marginalization status in Mexican states from 1980to 2013. Salud Publica Mex. 2016;58(2):179-186. https://doi.org/10.21149/spm.v58i2.7787

  8. Arceo-Olaiz R, de-Anda-González J, Urbina-Ramírez S, de Zavaleta MS,Castillejos-Molina R, Gabilondo-Navarro F, et al. Los márgenes quirúrgicospositivos disminuyen la supervivencia cáncer específica de los pacientescon cáncer de próstata tratados con prostatectomía radical: experienciaen un centro de tercer nivel en México. Gac Med Mex. 2013;149:286-91.https://www.medigraphic.com/pdfs/gaceta/gm-2013/gm133g.pdf

  9. Ramírez-Buensuceso-Conde NA, Ávalos-Jiménez JC, Xochipiltecatl-MuñozJD, Cruz-Zárate A, Robles-Aviña JA, Luna-Martínez J. Prostatectomíaradical versus crioablación: supervivencia de los pacientes. Rev Mex Urol.2017;77(6):437-45. https://www.scielo.org.mx/pdf/rmu/v77n6/2007-4085-rmu-77-06-437.pdf

  10. Andrade-Platas JD, Fernández-Carreño AJ, Mata-Miranda M, Parraguirre-Martínez S, Morales-Montor JG, Pacheco-Gahbler, et al. Evolución delos pacientes con cáncer de próstata localmente avanzado tratados conprostatectomía radical. Rev Mex Urol. 2008;68(6):314-7. Available from:https://www.medigraphic.com/pdfs/uro/ur-2008/ur086c.pdf

  11. Gutiérrez-Juárez RR, Álvarez-Bañuelos MT, Morales-Romero J, Ortiz-Chacha CS, Sampieri-Ramírez CL. Lugar de residencia y grado de marginacióncomo factores pronósticos de supervivencia al cáncer de próstataen Veracruz, México. Rev Peru Med Exp Salud Publica. 2020;37(3):423-30.https://doi.org/10.17843/rpmesp.2020.373.4929

  12. González-Pier E, Barraza Lloréns M, Gutiérrez Delgado C, VargasPalacios A. Sistema de Protección Social en Salud. Elementos conceptuales,financieros y operativos. Mexico: FCE, Secretaría de Salud,Fundación Mexicana para la Salud, Instituto Nacional de Salud Pública,2007.

  13. Graham J, Baker M, Macbeth F, Titshall V. Guideline DevelopmentGroup. Diagnosis and treatment of prostate cancer: summary ofNICE guidance. BMJ. 2008;336(7644):610-12. https://doi.org/10.1136/bmj.39498.525706.AD

  14. Secretaría de Salud. Diagnóstico y tratamiento del cáncer de próstataen un segundo y tercer nivel de atención. Mexico: Secretaría de Salud,2010 [cited January 10, 2021]. Available from: http://ijc.gob.mx/arc/8/lV/i/GuíaPróstata.pdf

  15. Consejo Nacional de Población. Índices de Marginación 2015. Mexico:Consejo Nacional de Población, 2015 [cited January 10, 2021]. Availablefrom: https://www.gob.mx/conapo/documentos/indice-de-marginacion-2015-284579

  16. Quezada A, Espín-Arellano I, Morales-Carmona E, González-GonzálezE, Lina Palacio-Mejía L, et al. Implementación y validación de un métodoprobabilístico de vinculación de bases de datos poblacionales. En: Librode resúmenes del 18 Congreso Nacional de Salud Pública. Cuernavaca:Instituto Nacional de Salud Pública, 2019.

  17. Fine J, Gray R. A proportional hazards model for the subdistribution ofa competing risk. J Am Stat Assoc. 1999;94:496-509. https://doi.org/10.1080/01621459.1999.10474144

  18. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, etal. Global surveillance of cancer survival 1995-2009: analysis of individualdata for 25,676,887 patients from 279 population-based registries in 67countries (CONCORD-2). Lancet. 2015;385(9972);977-1010. https://doi.org/10.1016/S0140-6736(14)62038-9

  19. Restrepo JA, Bravo LE, García-Perdomo HA, García LS, Collazos P,Carbonell J. Prostate cancer in Cali, Colombia, 1962-2011: incidence,mortality and survival. Salud Publica Mex. 2014;56(5):440-7. https://doi.org/10.21149/spm.v56i5.7369

  20. Arias-Ortiz NE, de Vries E. Health inequities and cancer survivalin Manizales, Colombia: a population-based study. Colomb Med.2018;49(1):63-72. https://doi.org/10.25100/cm.v49i1.3629

  21. Comisión Económica para América Latina y el Caribe. Gasto en salud.Base de Datos de Inversión Social. CEPAL, 2018 [cited November 04,2021]. Available from: https://observatoriosocial.cepal.org/inversion/es/indicador/gasto-salud

  22. Tourinho-Barbosa RR, Pompeo AC, Glina S. Prostate cancerin Brazil and Latin America: epidemiology and screening. Int BrazJ Urol. 2016;42(6):1081-90. https://doi.org/10.1590/S1677-5538.IBJU.2015.0690

  23. DeRouen MC, Yang J, Jain J, Weden MM, Gomez SL, Shariff-Marco S.Disparities in prostate cancer survival according to neighborhood archetypes,a population-based study. Urology. 2022;163:138-47. https://doi.org/10.1016/j.urology.2021.05.085

  24. Vaidya V, Partha G, Karmakar M. Gender differences in utilization ofpreventive care services in the United States. J Womens Health (Larchmt).2012;21(2):140-5. https://doi.org/10.1089/jwh.2011.2876

  25. Basulto-Martínez M, Ojeda-Pérez JE, Velueta-Martínez IA, Cueto-VegaGJ, Flores-Tapia JP, González-Losa MDR. Prostate cancer early detectionamong primary care physicians in Mexico: A cross-sectional study. CirCir. 2021;89(2):163-9. https://doi.org/10.24875/CIRU.20000232

  26. Muñoz-Aguirre P, Huerta-Gutierrez R, Zamora S, Mohar A, Vega-VegaL, Hernández-Ávila JE, et al. Acute lymphoblastic leukaemia survival inchildren covered by Seguro Popular in Mexico: a national comprehensiveanalysis 2005-2017. Health Syst Reform. 2021;7(1):e1914897. https://doi.org/10.1080/23288604.2021.1914897

  27. Montaño JJ, Barceló A, Franch P, Galceran J, Ameijide A, Pons J, et al.Prostate cancer survival by risk and other prognostic factors in Mallorca,Spain. Int J Environ Res Public Health. 2021;18(21):11156. https://doi.org/10.3390/ijerph182111156

  28. Comisión Nacional de Protección Social en Salud. Informe de Resultadosdel Sistema de Protección Social en Salud. Mexico: CNPSS, 2019[cited November 10, 2021]. Available from: http://www.transparencia.seguro-popular.gob.mx/contenidos/archivos/transparencia/planesprogramaseinformes/informes/2019/Informe_Resultados_SPSS_2019.pdf

  29. Secretaría de Salud. Perfil epidemiológico de los tumores malignos enMéxico. Mexico: Secretaría de Salud, 2011 [cited November 04, 2021].Available from: https://epidemiologiatlax.files.wordpress.com/2012/10/p_epi_de_los_tumores_malignos_mc3a9xico.pdf

  30. Hernández B, Ramírez-Villalobos D, Romero M, Gómez S, AtkinsonC, Lozano R. Assessing quality of medical death certification: Concordancebetween gold standard diagnosis and underlying cause of deathin selected Mexican hospitals. Popul Health Metr. 2011;9:38. https://doi.org/10.1186/1478-7954-9-38

  31. Palacio-Mejía LS, Wheatley-Fernández JL, Ordoñez-Hernández I,López-Ridaura R, Lopez-Gatell Ramirez H, Hernandez-Avila M, et al.Estimación del exceso de mortalidad por todas las causas durante lapandemia del Covid-19 en México. Salud Publica Mex. 2021;63(2):211-24.https://doi.org/10.21149/12225

  32. Tervonen HE, Morrell S, Aranda S, Roder D, You H, Niyonsenga T, et al.The impact of geographic unit of analysis on socioeconomic inequalitiesin cancer survival and distant summary stage - a population-based study.Aust N Z J Public Health. 2017;41 (2):130-6. https://doi.org/10.1111/1753-6405.12608

  33. Hammarsten P, Josefsson A, Thysell E, Lundholm M, Hägglöf C, Iglesias-Gato D, et al. Immunoreactivity for prostate specific antigen and Ki67 differentiatessubgroups of prostate cancer related to outcome. Mod Pathol.2019;32(9):1310-1319. https://doi.org/10.1038/s41379-019-0260-6

  34. Reich MR. Restructuring health reform, mexican style. Health SystReform. 2020;6(1):1-11. https://doi.org/10.1080/23288604.2020.1763114




2020     |     www.medigraphic.com